EXICURE INC (XCUR) Stock Price, Quote, News and Overview
NASDAQ:XCUR - Nasdaq - US30205M3097 - Common Stock - Currency: USD
XCUR Quote, Performance and Key Statistics
EXICURE INC
NASDAQ:XCUR (1/23/2025, 4:29:46 PM)
After market: 12.8 -0.86 (-6.3%)13.66
+3.29 (+31.73%)
The current stock price of XCUR is 13.66 USD. In the past month the price decreased by -34.12%. In the past year, price increased by 294%.
XCUR Latest News, Press Releases and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Top movers analysis in the middle of the day on 2025-01-23: top gainers and losers in today's session.
Which stocks are gapping on Thursday?
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Curious about the stocks that are showing activity before the opening bell on Thursday?
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
These stocks are moving in today's after hours session
Wednesday's after hours session: top gainers and losers
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes
GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.
XCUR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.88 | 301.60B | ||
| AMGN | AMGEN INC | 14.46 | 149.37B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.80B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862.22 | 113.24B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.29 | 76.33B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.43B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.68B | ||
| BIIB | BIOGEN INC | 8.8 | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.18B |
Related screens
About XCUR
Company Profile
Exicure Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Chicago, Illinois and currently employs 6 full-time employees. The company went IPO on 2018-05-09. Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The firm is into exploring strategic alternatives to maximize stockholder value. The company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly traded organization. The firm is exploring transactions in industries unrelated to its historical operations. The company does not generate any revenues. The company wholly owned subsidiary is Exicure Operating Company that holds all material assets and conducts all business activities and operations of the Company.
Company Info
EXICURE INC
2430 N. Halsted St.
Chicago ILLINOIS 60614 US
CEO: David A. Giljohann
Employees: 5
Company Website: https://www.exicuretx.com/
Investor Relations: http://investors.exicuretx.com/overview/default.aspx
Phone: 18476731700
XCUR FAQ
What is the price of XCUR?
The current price of XCUR is 13.66 USD.
What is the symbol for EXICURE INC?
The exchange symbol of EXICURE INC is XCUR and it is listed on the Nasdaq exchange.
On which exchange is XCUR listed?
XCUR is listed on the Nasdaq exchange.
Is XCUR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for XCUR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of XCUR.
Does XCUR pay dividends?
XCUR does not pay a dividend.
What is the Price/Earnings (PE) ratio of XCUR?
XCUR does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.26).
What is the Short Interest ratio of XCUR?
The outstanding short interest for XCUR is 17.44% of its float.
XCUR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to XCUR. When comparing the yearly performance of all stocks, XCUR is one of the better performing stocks in the market, outperforming 99.14% of all stocks.
XCUR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to XCUR. The financial health of XCUR is average, but there are quite some concerns on its profitability.
XCUR Financial Highlights
Over the last trailing twelve months XCUR reported a non-GAAP Earnings per Share(EPS) of -2.26. The EPS decreased by -231.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.69% | ||
| ROE | -259.35% | ||
| Debt/Equity | 0 |
XCUR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to XCUR. The Buy consensus is the average rating of analysts ratings from 6 analysts.